Skip to content

JBIO JBIO Income Tax

Income Tax at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$221.5M+163%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
-$120K-408%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$40K-9.1%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$12K+50.0%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$64K+23.1%
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
$0+100%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's income tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's income tax?
JBIO (JBIO) reported income tax of $16K in Q1 2026.
How has JBIO's income tax changed year-over-year?
JBIO's income tax increased by 10.3% year-over-year, from $14.5K to $16K.
What is the long-term trend for JBIO's income tax?
Over 3 years (2021 to 2025), JBIO's income tax has grown at a 168.4% compound annual growth rate (CAGR), from $3K to $58K.
What does income tax mean?
Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.